Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT05858632
PHASE4
Immune Spatial Features of Guselkumab Cutaneous Response
Sponsor: University of California, San Francisco
View on ClinicalTrials.gov
Summary
This study examines the effect of IL-23 blockade with Guselkumab on the immune cells of scalp psoriasis lesions.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2023-07-01
Completion Date
2026-06-30
Last Updated
2023-08-28
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Guselkumab
Guselkumab treatment for \~ 9 months
Locations (1)
University of California San Francisco
San Francisco, California, United States